Mupirocin calcium hydrate BRL-4910A calcium hydrate; Pseudomonic acid calcium hydrate|cas:115074-43-6|西域试剂

Mupirocin calcium hydrate BRL-4910A calcium hydrate; Pseudomonic acid calcium hydrate,98.05%

产品编号：Bellancom-N7068| CAS NO：115074-43-6| 分子式：C₂₆H₄₆O₁₀| 分子量：538.68

Mupirocin calcium hydrate是从 Pseudomonas fluorescens 中分离得到的一种有口服活性的抗生素。Mupirocin calcium hydrate通过可逆地抑制异亮氨酸转移RNA，从而抑制细菌蛋白和RNA的合成而发挥抗菌作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-N7068	￥1000.00	杭州北京（现货）
Bellancom-N7068	￥1600.00	杭州北京（现货）
Bellancom-N7068	￥2600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Mupirocin calcium hydrate BRL-4910A calcium hydrate; Pseudomonic acid calcium hydrate

产品介绍

Mupirocin (BRL-4910A, Pseudomonic acid) calcium hydrate 可从 Pseudomonas fluorescens 中分离得到，是一种有口服活性的抗生素。Mupirocin calcium hydrate 通过可逆地抑制异亮氨酸转移 RNA，从而抑制细菌蛋白和 RNA 的合成而发挥抗菌作用。

生物活性

Mupirocin (BRL-4910A, Pseudomonic acid) calcium hydrate is an orally active antibiotic isolated from Pseudomonas fluorescens. Mupirocin calcium hydrate apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis.

体外研究

Mupirocin (BRL-4910A, Pseudomonic acid) calcium hydrate (0-100 μM; 48 h) shows antibacterial effect against staphylococci, streptococci and certain gram-negative bacteria, with MIC values range from 0.06-0.25 μg/mL (MIC₅₀ =0.12 μg/mL, MIC₉₀ =0.25 μg/mL).
Mupirocin calcium hydrate is highly bound (95% bound) to human serum protein, thus results in activity inhibition in the presence of human serum.
Mupirocin calcium hydrate apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis.
Mupirocin calcium hydrate (2% ointment) reduces pro-inflammatory cytokines IL-1β and IL-17 level, decreases tumor necrosis factor-alpha (TNF-α) expression, and increases the leavel of vascular endothelial growth factor (VEGF)^[4].
Mupirocin calcium hydrate inhibits MS (S. epidermidis ATCC 12228), MR (S. epidermidis (Se56-99)), and VIR (S. epidermidis (Se43-98)) with MICs of 0.25, 1.26, 1.59 mg/L^[5].
Note: MIC, the minimum inhibition concentration.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Staphylococcus aureus
Concentration:	0-100 μM/mL
Incubation Time:	24, 48 hours
Result:	Resulted in a 90 to 99% reduction at 24 h, with MIC values ranged from 0.12-1.0 μM/mL and MBC values ranged from 4.0-32 μM/mL at 48 h.

体内研究
(In Vivo)

MRSA: Meticillin-resistant Staphylococcus aureus
Mupirocin (BRL-4910A, Pseudomonic acid) calcium is well absorbed after oral and parenteral administration but serum antibiotic concentrations were short-lived as a result of extensive degradation to the antibacterially inactive metabolite, monic acid A.
Mupirocin calcium (2% ointment; external administration; twice daily; 3-6 d) decreases the total bacterial loads in the skin lesions with either topical treatment.
Mupirocin calcium (2% ointment; external administration; 4 d) alleviates MRSA-infected pressure ulcers in mice^[4].
Mupirocin calcium (100 mg/mL; s.c.; 7 d) exerts prevention efficacy against vascular prosthetic graft infection due to Staphylococcus epidermidis^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MRSA skin infection model in mice (10-12 weeks old)
Dosage:	2% ointment
Administration:	External administration; twice daily; 3-6 days
Result:	Reduced the total bacterial loads in the skin lesions, and decreased by 2.0, 5.1 log₁₀ CFU on day 3 and 6, respectively.

Animal Model:	Diabetic pressure ulcer mouse model (33.2-39.2 g)^[4]
Dosage:	2% ointment
Administration:	External administration; 4 days
Result:	Resulted less superficial mats of bacterial colonies, and improved histopathology evaluation.

Animal Model:	Adult male Wistar rats (weight 275-325 g)^[5]
Dosage:	Impregnated with 100 μg of mupirocin/mL; segments:1.5 cm *1 cm²
Administration:	Subcutaneous implantation; 7 days
Result:	Resulted in preventing S. epidermidis infection of the graft in a rat model with spontaneously bound to collagen-sealed Dacron grafts.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MRSA skin infection model in mice (10-12 weeks old)
Dosage:	2% ointment
Administration:	External administration; twice daily; 3-6 days
Result:	Reduced the total bacterial loads in the skin lesions, and decreased by 2.0, 5.1 log₁₀ CFU on day 3 and 6, respectively.

Animal Model:	Diabetic pressure ulcer mouse model (33.2-39.2 g)^[4]
Dosage:	2% ointment
Administration:	External administration; 4 days
Result:	Resulted less superficial mats of bacterial colonies, and improved histopathology evaluation.

Animal Model:	Adult male Wistar rats (weight 275-325 g)^[5]
Dosage:	Impregnated with 100 μg of mupirocin/mL; segments:1.5 cm *1 cm²
Administration:	Subcutaneous implantation; 7 days
Result:	Resulted in preventing S. epidermidis infection of the graft in a rat model with spontaneously bound to collagen-sealed Dacron grafts.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MRSA skin infection model in mice (10-12 weeks old)
Dosage:	2% ointment
Administration:	External administration; twice daily; 3-6 days
Result:	Reduced the total bacterial loads in the skin lesions, and decreased by 2.0, 5.1 log₁₀ CFU on day 3 and 6, respectively.

Animal Model:	Diabetic pressure ulcer mouse model (33.2-39.2 g)^[4]
Dosage:	2% ointment
Administration:	External administration; 4 days
Result:	Resulted less superficial mats of bacterial colonies, and improved histopathology evaluation.

Animal Model:	Adult male Wistar rats (weight 275-325 g)^[5]
Dosage:	Impregnated with 100 μg of mupirocin/mL; segments:1.5 cm *1 cm²
Administration:	Subcutaneous implantation; 7 days
Result:	Resulted in preventing S. epidermidis infection of the graft in a rat model with spontaneously bound to collagen-sealed Dacron grafts.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (185.64 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8564 mL	9.2819 mL	18.5639 mL
5 mM	0.3713 mL	1.8564 mL	3.7128 mL
10 mM	0.1856 mL	0.9282 mL	1.8564 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.25 mg/mL (2.32 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (2.32 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.25 mg/mL (2.32 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (2.32 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.25 mg/mL (2.32 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (2.32 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

参考文献

. Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495-8. [Content Brief]

. Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6(10):761-70. [Content Brief]

. Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep. 42(3):272-5. [Content Brief]

[4]. Mohammad H, Abutaleb NS, Dieterly AM, Lyle LT, Seleem MN. Investigating auranofin for the treatment of infected diabetic pressure ulcers in mice and dermal toxicity in pigs. Sci Rep. 2021 May 25;11(1):10935. [Content Brief]

[5]. Giacometti A, et al. Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection. Antimicrob Agents Chemother. 2000 Oct. 44(10):2842-4. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

危险品运输编码	NONH for all modes of transport

1. 物质的识别

产品名：	Mupirocin calcium
CAS号：	115074-43-6
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Mupirocin calcium
别名：	pseudomonic acid A
分子式：	C52H90CaO20
分子量：	1075.34

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

[1]. Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495-8.

[2]. Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6(10):761-70.

Mupirocin calcium hydrate BRL-4910A calcium hydrate; Pseudomonic acid calcium hydrate,98.05%

Mupirocin calcium hydrate BRL-4910A calcium hydrate; Pseudomonic acid calcium hydrate

化学品安全说明书(MSDS)

质检证书(COA)

1. 物质的识别

2. 合成/成分数据

3. 急救措施

4. 消防措施

5. 泄漏应急处理

6. 处理和储存

7. 接触控制和个人防护

8. 稳定性和反应活性

9. 毒性资料

10. 生态资料

11. 废弃处置

12. 运输信息

13. 法规信息

14. 其他信息

在线咨询